注册 | 登录 | 充值

首页-> 学术资讯 -> 文献解读

柳叶刀:球囊导管与阴道前列腺素用于引产是否有效?

文献解读

2022-11-21      

1002 0


引产是全球最常见的产科干预措施之一。球囊导管和阴道前列腺素在引产中被广泛用于使宫颈成熟。我们的目的是比较这两种诱导方法的有效性和安全性。


个体参与者数据来自12项研究,共计5460名参与者。与阴道前列腺素相比,球囊导管未导致显著差异的剖宫产率(12项试验,5,414名女性;粗发病率为27.0%;校正(OR=1.09, 95% CI 0.95 ~ 1.24; I2=0%)、疾病进展失败的剖宫产(11项试验,4601名女性;aOR 1.20, 95% CI 0.91 ~ 1.58; I2=0%),或胎儿窘迫的剖宫产(10项试验,4,441名女性;aOR 0.86, 95% CI 0.71 ~ 1.04; I2=0%)。


在引产中,球囊导管和阴道前列腺素具有相当的剖腹产率和产妇安全状况,但球囊导管导致较少的不良围产期事件。


Abstract

Background: Induction of labour is one of the most common obstetric interventions globally. Balloon catheters and vaginal prostaglandins are widely used to ripen the cervix in labour induction. We aimed to compare the effectiveness and safety profiles of these two induction methods.


Methods: We did an individual participant data meta-analysis comparing balloon catheters and vaginal prostaglandins for cervical ripening before labour induction. We systematically identified published and unpublished randomised controlled trials that completed data collection between March 19, 2019, and May 1, 2021, by searching the Cochrane Library, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, and PubMed. Further trials done before March 19, 2019, were identified through a recent Cochrane review. Data relating to the combined use of the two methods were not included, only data from women with a viable, singleton pregnancy were analysed, and no exclusion was made based on parity or membrane status. We contacted authors of individuals trials and participant-level data were harmonised and recoded according to predefined definitions of variables. Risk of bias was assessed with the ROB2 tool. The primary outcomes were caesarean delivery, indication for caesarean delivery, a composite adverse perinatal outcome, and a composite adverse maternal outcome. We followed the intention-to-treat principle for the main analysis. The primary meta-analysis used two-stage random-effects models and the sensitivity analysis used one-stage mixed models. All models were adjusted for maternal age and parity. This meta-analysis is registered with PROSPERO (CRD42020179924).


Findings: Individual participant data were available from 12 studies with a total of 5460 participants. Balloon catheters, compared with vaginal prostaglandins, did not lead to a significantly different rate of caesarean delivery (12 trials, 5414 women; crude incidence 27·0%; adjusted OR [aOR] 1·09, 95% CI 0·95-1·24; I2=0%), caesarean delivery for failure to progress (11 trials, 4601 women; aOR 1·20, 95% CI 0·91-1·58; I2=39%), or caesarean delivery for fetal distress (10 trials, 4441 women; aOR 0·86, 95% CI 0·71-1·04; I2=0%). The composite adverse perinatal outcome was lower in women who were allocated to balloon catheters than in those allocated to vaginal prostaglandins (ten trials, 4452 neonates, crude incidence 13·6%; aOR 0·80, 95% CI 0·70-0·92; I2=0%). There was no significant difference in the composite adverse maternal outcome (ten trials, 4326 women, crude incidence 22·7%; aOR 1·02, 95% CI 0·89-1·18; I2=0%).


Interpretation: In induction of labour, balloon catheters and vaginal prostaglandins have comparable caesarean delivery rates and maternal safety profiles, but balloon catheters lead to fewer adverse perinatal events.


文章连接:

www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01845-1/fulltext



科研资讯(站内):

百度浏览   来源 : 医微客   


版权声明:本网站所有注明来源“医微客”的文字、图片和音视频资料,版权均属于医微客所有,非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源:”医微客”。本网所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,转载仅作观点分享,版权归原作者所有。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。 本站拥有对此声明的最终解释权。

科研搜索(百度):医学科研





发表评论

注册或登后即可发表评论

登录注册

全部评论(0)

没有更多评论了哦~

科研资讯 更多>>
  • 肿瘤电场治疗Optune Lua获批治疗..
  • 成本更低的实体瘤抗癌新星:CAR-..
  • 文献速递-子宫内膜癌中的卵黄囊..
  • Nature|MSCs首次用于人体跟腱病..
  • 推荐阅读 更多>>
  • 柳叶刀:Q-122作为一种新型非激..
  • ENJM:PD-1阻断法治疗错配修复缺..
  • ENJM:德喜曲妥珠单抗 vs 恩美曲..
  • Nat Commun:派姆单抗、曲妥珠单..
    • 相关阅读
    • 热门专题
    • 推荐期刊
    • 学院课程
    • 医药卫生
      期刊级别:国家级期刊
      发行周期:暂无数据
      出版地区:其他
      影响因子:暂无数据
    • 中华肿瘤
      期刊级别:北大核心期刊
      发行周期:月刊
      出版地区:北京
      影响因子:1.90
    • 中华医学
      期刊级别:CSCD核心期刊
      发行周期:周刊
      出版地区:北京
      影响因子:0.94